FDA Tightens CAR-T Approval Standards, Mandating Randomized Controlled Trials for Future Therapies
核心洞察
The FDA is raising approval standards for CAR-T (搜索) therapies by requiring randomized controlled trials with survival or time-to-event endpoints as the preferred approach for regulatory filings.
Single-arm trials, which supported all seven currently approved CAR-T (搜索) therapies, will no longer be sufficient for full approval, though they may still support accelerated approval in rare cancers.
Companies must now test experimental CAR-T (搜索) therapies against existing standard treatments, including other approved CAR-T products, with control groups selected based on available treatments and ethical considerations.
The FDA is implementing stricter approval standards for CAR-T (搜索) cell therapies, requiring randomized controlled trials (RCTs) as the preferred approach for future regulatory submissions. This represents a significant shift from current practices where single-arm trials without control groups have been acceptable for bringing these innovative cancer treatments to market.
New Regulatory Framework
Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research (CBER), outlined the agency's evolving perspective in a recent Journal of the American Medical Association (JAMA) publication. The new standards will require CAR-T (搜索) developers to conduct full randomized, controlled trials with "a survival or acceptable time-to-event endpoint" rather than relying solely on single-arm studies.
The selection of control groups "must take into account the available standard treatments, including approved CAR-T (搜索) cell therapies, ethical considerations, and most importantly the ability to reliably distinguish the outcome caused by an investigational product from the outcomes caused by other factors," according to Prasad and his colleagues.
These factors could include the natural history of the disease, patient or clinician expectations, or other concurrent treatments that might influence outcomes.
Impact on Current Market
All seven CAR-T (搜索) therapies currently on the market received approval based on single-arm trials, highlighting the magnitude of this regulatory shift. The change comes as the FDA simultaneously loosened safety monitoring requirements by eliminating risk evaluation and mitigation strategies (REMS) for already-marketed therapies targeting CD19 (搜索) and BCMA (搜索), which the agency said would improve accessibility.
Limited Exceptions
The FDA will maintain some flexibility for specific circumstances. Single-arm trials may continue to be acceptable in rare cancers and for patients whose disease has relapsed despite multiple prior therapies. Response rate data will still serve as a suitable endpoint for accelerated approval, but converting to full licensure will require stronger endpoints like overall survival generated through RCTs.
Industry Challenges
These heightened requirements add pressure to a cell therapy sector already facing significant challenges. Recent months have witnessed several high-profile exits and program discontinuations. Regeneron terminated its early-stage bbT369 CAR-T (搜索) therapy in October 2024, which it had acquired from 2seventybio (搜索) in January 2024. The asset was being tested in relapsed or refractory B-cell non-Hodgkin's lymphoma (搜索), with a company spokesperson citing a "strategic business decision."
CAR-T (搜索) specialist Cargo Therapeutics exemplified the sector's struggles when it fired 90% of its staff and halted all development work in March 2024 after its lead asset failed a Phase II study in January.
Immediate Implications
The new guidelines could directly affect ongoing programs, including the collaboration between Gilead and Arcellx on anti-BCMA (搜索) therapy anitocabtagene autoleucel (anito-cel). The partners are currently conducting the registrational Phase II iMMagine-1 study, which does not include a control arm.
According to Prasad and his co-authors, the FDA's perspective on CAR-Ts continues to evolve while maintaining "high evidentiary standards for approval" and retaining "regulatory flexibility when necessary, to advance the development of these products."